Trials / Completed
CompletedNCT02268032
Assess the Effect of Dehydroepiandrosterone (DHEA) or Other Androgenic Agents Over Markers of Ovarian Reserve
Assess the Effect of DHEA or Other Androgenic Agents on Ovarian Reserve Markers in Women With Diminished Ovarian Reserve
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 94 (actual)
- Sponsor
- Laboratorios Andromaco S.A. · Industry
- Sex
- Female
- Age
- 38 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study was conducted to evaluate the effect of a continuous administration of dehydroepiandrosterone (DHEA) or other androgenic agents on ovarian reserve markers in women with diminished ovarian reserve (ROD), such as antral follicle count (AFC) and anti-Müllerian hormone (AMH) concentrations.
Detailed description
Healthy women attending the clinic of the Mother and Health Research Institute (IDIMI) were invited to participate, if they could not become pregnant due to surgical sterilization, and if they presented no contraindications to use androgen therapy. Project Objectives : The general objective was to evaluate pharmacokinetic parameters of three vaginal rings containing DHEA, testosterone, or combination of both hormones in women. Secondary objectives were to assess effects on the hormonal profile, tolerability and incidence of adverse events. * DHEA and/or, testosterone levels * Estradiol, follicle stimulating hormone (FSH), sex hormone binding globulin (SHBG), androstenedione, morning cortisol, insulin growth factor 1 (IGF-1) levels * Tolerability and safety assessment by the use of the vaginal ring. * The incidence of adverse events
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DHEA | DHEA 2.2 g in vaginal ring |
| DRUG | Another Androgenic Agent (VRaA) | Testosterone 35 mg in vaginal ring |
| DRUG | Fixed combination of 2 androgenic agents (VR2A) | DHEA 1.5 g/testosterone 25 mg fixed combination in vaginal ring |
Timeline
- Start date
- 2014-07-15
- Primary completion
- 2016-08-31
- Completion
- 2016-08-31
- First posted
- 2014-10-20
- Last updated
- 2019-05-29
Locations
1 site across 1 country: Chile
Source: ClinicalTrials.gov record NCT02268032. Inclusion in this directory is not an endorsement.